10 December 2018
Responding to news that the Scottish Medical Consortium (SMC) has approved the use of pertuzumab (Perjeta) for neo-adjuvant treatment of HER2-positive breast cancer, which is either locally advanced, inflammatory (a particular type of breast cancer) or early stage with a high risk of recurrence, Angela Harris, Head of Breast Cancer Care Scotland, says:
“After multiple attempts, this long-overdue decision finally brings women in Scotland, with a certain type of breast cancer, onto an equal footing with those in England. Care must not be one size fits all, and access to Perjeta will ultimately provide more effective, tailored treatment.
“We hear from women every day who are utterly devastated after losing a breast, often leaving them with rock-bottom body confidence and a shattered sense of self. Excitingly, this drug offers the chance to shrink the tumour, which can mean less invasive and dramatic surgery.
“It is now imperative that the SMC approves Perjeta next month for women living with secondary, incurable breast cancer. It’s absolutely outrageous that a life-extending drug is available across the border when women in Scotland are denied access, along with the precious extra time it can bring.”
For further information, please contact:
Breast Cancer Care Press Office: 020 7960 3463 (out of hours 07702 901 334)
About Breast Cancer Care
Breast Cancer Care is the only specialist UK wide charity providing support for women, men, family and friends affected by breast cancer. We’ve been caring for them, supporting them, and campaigning on their behalf since 1973.
Today, we continue to offer a unique range of support including reliable information, one-to-one support over the phone and online from nurses and people who’ve been there. We also offer local group support across the UK.
From the moment someone notices something isn’t right, through to their treatment and beyond, we’re there to help people affected by breast cancer feel more in control. www.breastcancercare.org.uk